bioRxiv · 10.64898/2026.06.11.730265
An EpCAM-Targeted Mirror-Image DNA Nanostructure for Precise Drug Delivery in Triple-Negative Breast Cancer
Abstract
Triple-negative breast cancer (TNBC) remains a major therapeutic challenge due to the lack of effective molecular targets and the dose-limiting off-target toxicity of conventional chemotherapy. Here, we design and construct a mirror-image DNA (L-DNA) nanostructure functionalized with an epithelial cell adhesion molecule (EpCAM)-specific aptamer for targeted delivery of doxorubicin (DOX) to TNBC cells. The L-DNA nanostructure retains thermodynamic properties comparable to natural D-DNA while exhibiting substantially enhanced resistance to nuclease and serum-mediated degradation due to its mirror-image chirality. Thermal melting and serum stability assays confirmed superior structural stability of the L-DNA nanostructure compared to D-DNA counterparts. In vitro cytotoxicity studies demonstrated that the EpCAM-targeted L-DNA nanostructure has the potential to selectively inhibit the growth of EpCAM-positive TNBC cells while reducing cytotoxicity in normal cells. These findings demonstrate that combining aptamer targeting with mirror-image DNA nanotechnology provides a stable and selective nanoplatform for chemotherapeutic delivery, which can potentially improve the precision and therapeutic efficacy of treatment for aggressive breast cancers.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Wu, S., Farkaly, T., Zhang, W.. 2026-06-15. An EpCAM-Targeted Mirror-Image DNA Nanostructure for Precise Drug Delivery in Triple-Negative Breast Cancer. https://doi.org/10.64898/2026.06.11.730265
Cite the original work for its findings. Save a collection to share your selection of sources.